by ltsiwpadmin | Jun 12, 2017 | News
Michael Carter Published: 12 July 2017 Over a third of people with HIV have non-alcoholic fatty liver disease (NAFLD) in the absence of hepatitis B or C, according to the results of a meta-analysis and systematic review published in AIDS. Metabolic disorders including...
by ltsiwpadmin | Jun 6, 2017 | News
Viking Therapeutics, Inc. June 6, 2017 SAN DIEGO, June 6, 2017 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine...
by ltsiwpadmin | Jun 5, 2017 | News
Can-Fite BioPharma Ltd. June 5, 2017 PETACH TIKVA, Israel, June 5, 2017 /PRNewswire/ — Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory...
by ltsiwpadmin | Jun 5, 2017 | News
Published: June 5, 2017 Boston—Serum microRNA signatures have the potential to identify patients with non-alcoholic steatohepatitis who need treatment for the condition, researchers have found. The discovery, if confirmed, would be welcome news given that rates of...
by ltsiwpadmin | Jun 1, 2017 | Policy & Public Affairs, Publications
Abstract Recent studies report a prevalence of non-alcoholic fatty liver disease (NAFLD) of between 70% and 80% in patients with metabolic syndrome (MS) and type 2 diabetes mellitus (T2DM). Nevertheless, it is not possible to differentiate between simple steatosis and...
Recent Comments